InvestorsHub Logo

Craig305

07/26/23 6:51 PM

#33025 RE: Biotech_Tradez #33024

ENDV is never on time for any catalyst.

John_Vallay

07/27/23 6:27 PM

#33026 RE: Biotech_Tradez #33024

A valuation on paper means nothing. No investment fund is going to trust Alan Collier by making an investment into his company, companies or spin offs.

Investment firms conduct a great deal of due diligence and there are so many red marks on Alan Collier which means no real, sophisticated & investment firm will give him money.

Alan has never raised any money from investment firms while running Endonovo, and no one can ever say convertible notes are investments. They are toxic financings that are done with no due diligence and in most cases the funder never even meets the CEO because the CEO and the business are irrelavent. The only thing that matters to a convertible note investor is liquidity in the stock.

A public company that accepts convertible notes has always, and when I say always, I mean 100% of the time, seen the market cap go down. Never has there been a company that has had stock price appreciation after taking a convertible note.

Endonovo is that company now, and has been for many years, and the stock price shows that to be true.

As for valuation report, whomever Alan Collier is paying for this so-called valuation report will write whatever Alan wants written and it does nothing other than give him some sort of document that he can give to unsophisticated investors.

Craig305

03/27/24 11:17 AM

#33200 RE: Biotech_Tradez #33024

On the Sofpulse investor website, they are still referencing the 2018 valuation report of $75M.
Looks like the updated "true" valuation is never going to happen.